Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of divarasib combined with pembrolizumab compared with pembrolizumab plus pemetrexed and carboplatin or cisplatin for adults with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have not received prior treatment. This phase 3 randomized study aims to find the best first-line therapy option for this specific lung cancer type. Participants are randomly assigned to one of two groups one group receives divarasib orally once daily and pembrolizumab through intravenous infusion every three weeks, while the other group receives pembrolizumab, pemetrexed, and carboplatin or cisplatin all by intravenous infusion every three weeks. The study treatments are given as first-line therapy, and participants are monitored for up to approximately five years. During the study, participants undergo regular assessments including scans to measure tumor response, evaluations of lung cancer symptoms like cough and breathlessness, quality of life questionnaires, and monitoring for side effects. Researchers track progression-free survival and overall survival for up to about five years. Safety and symptom severity are closely followed throughout the study, providing comprehensive data on treatment impact and participant well-being.
Actively Recruiting
Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.
Actively Recruiting
Researchers are evaluating whether continuing cetuximab treatment beyond first-line progression can improve outcomes in adults with metastatic colorectal cancer who have tumors that are RAS and BRAF wild-type. This Phase 3 clinical trial aims to compare chemotherapy combined with cetuximab versus chemotherapy combined with bevacizumab, focusing on tumor response, progression-free survival, overall survival, and safety. The study builds on prior trials suggesting potential benefits of cetuximab continuation in this patient group. Participants will be randomly assigned to receive either FOLFOX or FOLFIRI chemotherapy combined with cetuximab experimental group or bevacizumab control group. Treatments are given every two weeks, with cetuximab administered as a 120-minute intravenous infusion at 500 mgm and bevacizumab at 5 mgkg. Therapy continues until disease progression, unacceptable side effects, or patient withdrawal. Tumor response will be assessed by independent review using RECIST criteria. During the study, patients undergo regular CT or MRI scans, laboratory tests, and clinical evaluations. Biological samples such as tumor tissue, blood, and stool are collected for research on resistance mechanisms and the gut microbiome. The primary measure is the overall response rate assessed up to 48 months, with secondary outcomes including overall survival, progression-free survival, and safety monitored throughout treatment and up to 30 days after the last dose. Participation lasts through treatment and follow-up periods up to several years.
Actively Recruiting
Researchers are evaluating neladalkib NVL-655 compared to alectinib in patients with treatment-naive, ALK-positive advanced Non-Small Cell Lung Cancer NSCLC. This Phase 3, randomized, controlled, open-label study aims to see if neladalkib can better prolong progression-free survival in this patient population. Patients have confirmed ALK rearrangement and have not received prior systemic anticancer treatment for NSCLC except certain chemotherapy under specific conditions. Participants are randomly assigned in equal numbers to receive either neladalkib at 150mg once daily or alectinib at 600mg twice daily, both given orally. The study treatment continues as per protocol, with approximately 225 patients in each treatment arm. This trial evaluates multiple outcomes including progression-free survival, overall survival, intracranial response rates, and safety measures over a period of up to five years after the first patient is dosed. Throughout the study, participants undergo regular assessments including imaging to measure tumor response and progression, laboratory tests to monitor safety, and patient-reported questionnaires to evaluate quality of life and lung cancer symptoms. Safety and adverse events are closely monitored. The total duration of participation can last up to five years, allowing for long-term observation of treatment effects and outcomes.
Actively Recruiting
Researchers are evaluating two treatment options for patients with metastatic colorectal cancer whose disease has worsened after standard therapies. This phase II, open-label, multicenter clinical trial compares a rechallenge treatment using irinotecan plus cetuximab to the current standard of care, trifluridinetipiracil plus bevacizumab, as third-line therapy. Patients are selected based on specific molecular features of their cancer identified through circulating tumor DNA analysis from a blood sample. The main goal is to see if the rechallenge treatment results in a higher tumor response rate compared with the standard therapy. Participants are randomly assigned to one of two groups. The experimental group receives cetuximab combined with irinotecan administered every two weeks. The control group receives oral trifluridinetipiracil on a cycle of 28 days along with bevacizumab every two weeks. Treatment continues until the disease worsens, side effects become unacceptable, or the participant chooses to stop. Tumor response is regularly checked using CT or MRI scans following RECIST criteria. After disease progression, switching to the other treatment may be considered. During the trial, participants undergo scheduled tumor assessments, safety and tolerability monitoring, and quality of life questionnaires. Adverse events are tracked from the first dose until 30 days after the last dose. The study measures objective response rate primarily, as well as progression-free survival, overall survival, treatment exposure, and quality of life over up to 36 months. Long-term follow-up will assess survival outcomes, with treatments given under medical supervision until progression or withdrawal.